Immunogenicity of long-lasting recombinant factor VIII products by Ing, Mathieu et al.
Immunogenicity of long-lasting recombinant factor VIII
products
Mathieu Ing, Nimesh Gupta, Maud Teyssandier, Bernard Maille`re, Marc
Pallardy, Sandrine Delignat, Se´bastien Lacroix-Desmazes
To cite this version:
Mathieu Ing, Nimesh Gupta, Maud Teyssandier, Bernard Maille`re, Marc Pallardy, et al.. Im-
munogenicity of long-lasting recombinant factor VIII products. Cellular Immunology, Elsevier,
2016, 301, pp.40-48. <10.1016/j.cellimm.2015.12.006>. <hal-01292437>
HAL Id: hal-01292437
http://hal.upmc.fr/hal-01292437
Submitted on 23 Mar 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
Immunogenicity of long-lasting recombinant factor VIII products 
Mathieu Ing
1,2,3
, Nimesh Gupta
4
, Maud Teyssandier
1,2,3
, Bernard Maillère
5
, Marc Pallardy
6
, 
Sandrine Delignat
1,2,3
, Sébastien Lacroix-Desmazes
1,2,3
 on behalf of the ABIRISK consortium 
 
1
Sorbonne Universités, Université Pierre et Marie Curie, UMR_S 1138, Centre de Recherche 
des Cordeliers, F-75006, Paris, France; 
2
INSERM, UMR_S 1138, Centre de Recherche des 
Cordeliers, F-75006, Paris, France; 
3
Sorbonne Paris Cité, Université Paris Descartes, UMR_S 
1138, Centre de Recherche des Cordeliers, F-75006, Paris, France; 
4
National Institute of 
Immunology, New Dehli, India; 
5
CEA-Saclay Institute of Biology and Technologies, Gif sur 
Yvette, France; 
6
INSERM, UMR996, Faculté Pharmacie, Université Paris Sud, France. 
 
Corresponding author. Sébastien Lacroix-Desmazes, INSERM UMR_S 1138, Centre de 
Recherche des Cordeliers, Paris, F-75006 France - Tel: 01 44 27 82 02 - Fax: 01 44 27 81 94 
sebastien.lacroix-desmazes@crc.jussieu.fr 
 
Abbreviations. APC, antigen-presenting cells ; BcR, B cell receptor ; EMA, European 
Medicines Agency ; Fc, crystallizable fragment ; FcγR, receptor for IgG Fc portion ; FcRn, 
neonatal Fc receptor ; FVIIa, activated factor VII ; FVIII, Factor VIIII ; GLP-1, glucagon-like 
peptide 1 ; HA1, hemagglutinin ; HSA, human serum albumin ; IgG, immunoglobulin G ; 
IgM, immunoglobulin M ; LRP-1, lipoprotein receptor protein 1 ; MHC, major 
histocompatibility complex ; PEG, polyethylene glycol ; PTPs, previously treated patients ; 
PUPs, previously untreated patients ; Tregs, regulatory T cells ; VWF, von Willebrand factor 
 
Abstract count: 158 words 
Word count:  4842 
 2 
References count: 82 references  
 3 
Abstract 
Replacement therapy for patients with hemophilia A using plasma-derived or recombinant 
factor VIII (FVIII) is complicated by the short half-life of the FVIII products and by the 
occurrence of neutralizing antibodies in a substantial number of patients. In the recent years, 
enormous efforts have been invested to develop new generations of coagulation factors with 
extended half-lives. Presumably, the use of long-lasting FVIII products should reduce the 
frequency of administration to the patients and drastically improve their quality of life. The 
question of their immunogenicity remains however unanswered as yet. The present review 
proposes a summary of the different strategies developed to enhance the half-life of FVIII, 
including fusion of FVIII to the Fc fragment of the human IgG1 or to human serum albumin, 
or attachment of polyethylene glycol. Based on the available literature, we hypothesize on the 
potential benefits or risks associated with each of the latter strategies in terms of 
immunogenicity of the newly derived hemostatic drugs. 
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Introduction 
The past decades have witnessed extraordinary improvement in the treatment of bleeding 
disorders. Progressing from the Stone Age, with the use of whole blood and cryoprecipitate 
infusion, we have evolved to a modern time where recombinant coagulation factors are 
administered. Congenital disorders such as hemophilia A, that display life-threatening 
bleeding manifestations, have benefitted utmost from the development of new generation 
therapeutic factor VIII (FVIII), owing to the implication and commitment of the 
pharmaceutical field. Simultaneously, clinical studies as well as the implication of clinicians 
and basic researchers have promoted new treatment regimens (prophylaxis rather than “on-
demand” treatment) that reduce the risks for hemarthrosis and arthropathy episodes and have 
improved the quality of life of hemophilic patients.  
Despite the quality of FVIII in terms of efficacy and viral safety, the short half-life of FVIII 
imposes frequent administrations to provide an optimal protection of the patients from 
bleeding episodes. This is understandably associated with a limited adherence of the patients 
to prophylaxis regimen, thereby resulting in a lack of complete protection and higher 
treatment costs. Accordingly, the most recent developments for therapeutic coagulation 
factors have focused on extending their half-life in the blood: recombinant factors with longer 
residual time in circulation would cumulate the benefice of reducing the frequency of 
administration, thus improving the compliance of patients, and increasing the bleed-free time-
span of the patients, thus reducing the risks for minor arthropathy-prone joint bleeds. In this 
context, several strategies are being exploited to optimize the pharmacokinetics of therapeutic 
FVIII, that include coupling of the effector protein to dimeric Fc fragments of human 
immunoglobulin G, to polyethylene glycol (PEG) or to human serum albumin (HSA).  
The treatment of patients with hemophilia A using exogenous FVIII is complicated by the 
immunogenicity of the infused FVIII. Indeed, up to 30% of patients with severe hemophilia 
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A, and up to 5% of patients with mild/moderate forms of the disease, develop anti-FVIII IgG 
antibodies following replacement therapy. The induced anti-FVIII IgG presumably affect the 
pharmacokinetics of the exogenously administered coagulation factors but, more critically, 
inhibit their pro-coagulant activity. The development of inhibitory anti-FVIII IgG, or ‘FVIII 
inhibitors’, represents a major clinical burden as well as a major societal concern owing to the 
additional costs that are associated with inhibitor management. To our knowledge, there is no 
available study that clearly establishes a correlation between the residual time of a molecule 
and its immunogenicity in humans. It is thus hazardous to predict the immunogenicity of 
long-acting FVIII products. Besides, FVIII exhibits a degree of immunogenicity that is 
unexpected given the fact that FVIII has no know pro-inflammatory role. In this review, we 
summarize the rationale for the different strategies developed to enhance the half-life of 
FVIII. Based on the available evidence, we further anticipate the consequences and 
limitations of coupling FVIII to ‘half-life enhancers’ for its immunogenicity in hemophilia A 
patients.  
 
Coupling therapeutic FVIII to human Fc fragments 
The interaction of the Fc domain of immunoglobulins with the neonatal Fc receptor (FcRn) 
has been known for years as a physiological mechanism that protects IgGs from catabolism 
and confers them a long half-life in the blood [1]. Therefore, IgGs of the IgG1, IgG2 and 
IgG4 sub-classes are known to circulate in the body with a half-life of 3 weeks. The FcRn is 
expressed at many sites and by different cell types in mammals, where it mediates IgG 
transcytosis and IgG recycling in a pH-dependent manner [1]. In particular, the FcRn 
expressed in the vascular endothelium participates in protection of IgG from degradation. 
Endothelial cells widely express FcRn and are able to internalize blood-borne molecules by 
pinocytosis. Under acidic pH in the early endosomes, the engulfed IgG binds the FcRn 
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through their CH2 domain. Upon further acidification of the endosomes, IgG-FcRn complexes 
are redirected from the lysosomal degradation compartment to the cell surface. At neutral pH, 
the bound IgG dissociates from FcRn and is released in the circulation. This property has been 
exploited to increase the residence time of coagulation factors in vivo. Besides, owing to the 
conformation of the Fc domain, Fc-fused proteins are generally endowed with improved 
biophysical characteristics in terms of stability and solubility. 
In particular, a new generation of recombinant FVIII, referred to as Eloctate™ in North 
America, has been developed by fusing the dimeric CH2-CH3 domains of the human IgG1 Fc 
to the recombinant B domain-deleted FVIII. The post-translational modifications on the FVIII 
moiety are similar to that found on the commercially available B domain-deleted FVIII 
product, and the dimeric Fc carries two additional asparagine-glycosylated moieties. The 
addition of the Fc domain substantially increases the plasma half-life of FVIII and thus 
reduces the dosing frequency necessary to achieve prophylaxis in the patients. Thus, studies 
in pre-clinical models of hemophilia A have shown that fusion of the Fc to B domain-deleted 
FVIII confers a 2-fold increased half-life over recombinant FVIII, while preserving the 
specific activity of FVIII [2]. Indeed, the functionality of the Fc-fused FVIII in correcting 
whole blood clotting time has been demonstrated in FVIII-deficient mice, a model of severe 
hemophilia A, as well as in hemophilic dogs. The Fc-fused FVIII demonstrates a 1.5-fold 
extended half-life in human clinical trials as well as reduced annualized bleeding rates as 
compared to its non-fused counterpart [3–5].  
From an immunogenicity standpoint, available data from clinical trials suggest that FVIII-Fc 
is a safe molecule since no inhibitor development has been reported under prophylaxis 
regimen [5,6]. It is important to note however that clinical trials have been performed only in 
previously treated patients (PTPs) with severe hemophilia A, who are at a lower risk of 
developing an alloimmune response to exogenous FVIII as compared to previously untreated 
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patients (PUPs) [7]. Ongoing clinical trials performed in PUPs in Europe, which are required 
by the European Medicines Agency (EMA) prior to release of the drug on the European 
market, shall bring additional evidence in the coming years.  
Presentation of Fc-fused FVIII as a magic drug devoid of immunogenicity needs to be 
confronted to the facts that therapeutic human monoclonal antibodies do induce neutralizing 
antibodies in a substantial number of patients [8] and the fused Fc domain has been used for 
enhancing the adjuvant properties of vaccine antigens [9,10]. Because the Fc portion of FVIII 
not only interacts with FcRn, but also with a number of receptors for the Fc portion of IgG 
(FcR), as well as receptors for Fc-linked glycans [11], there are little chances that the FVIII-
Fc fusion molecule will be immunologically inert. Yet, recent work by Krishnamoorty et al 
shows that the immune response to FVIII-Fc in FVIII-deficient mice, is less frequent, or less 
intense, than in the case of FVIII lacking the Fc fragment, when FVIII is injected at 50 IU/kg 
[12]. However, at higher concentrations, all FVIII products show the same degree of 
immunogenicity. The rest of this chapter is an attempt to anticipate the interactions of FVIII-
Fc with cells of the innate and adaptive immune system, and potential immunological 
consequences of infusing Fc-fused FVIII in patients.  
 
Fc-mediated immune interactions. Navarrete et al. have previously observed that the 
marginal zone in the spleen is the primary site of FVIII accumulation in hemophilic mice 
[13]. Recently published data comparing the half-life and biodistribution of recombinant 
FVIII and FVIII-Fc intravenously administered to FVIII-deficient mice suggest that the 
accumulation of both molecules in the spleen does not show drastic differences [14]. The data 
also show that, as is the case for exogenous recombinant FVIII, the half-life and bio-
distribution of FVIII-Fc is largely dependent upon its interaction with endogenous von 
Willebrand factor (VWF). Interestingly, in view of the plethora of Fc receptors and Fc-
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binding cellular proteins expressed on immune cells, one may anticipate that FVIII-Fc is more 
prone to interact with immune cells than its native FVIII counterpart. In particular, one might 
foresee a synergistic effect of Fc-dependent and FVIII-dependent interactions with different 
types of endocytic receptors expressed by the same cells, although any repercussion in terms 
of immune activation or immune tolerance induction remains speculative.  
Dendritic cells, monocytes, macrophages and neutrophils are the primary immune cells 
participating in the initiation of immune responses. Provided the constitutive expression of 
various Fc receptors on these immune cells [15,16], it is anticipated that FVIII-Fc will 
interact with the latter cell types via its Fc domain, in addition to accumulating at the site of 
vascular injury. In this context, we may expect a differential assessment of FVIII and FVIII-
Fc by the immune system, although predicting whether this will lead to increased or reduced 
immunogenicity is impossible. Dendritic cells are known to simultaneously express both the 
activating and inhibitory FcR. Presumably, FVIII-Fc-mediated signaling through the 
inhibitory FcRIIB on dendritic cells should favor peripheral tolerance (Figure 1B), either by 
inhibiting dendritic cell activation or by limiting the processing of the exogenously acquired 
antigen [17]. However, the outcome of the immunological processing of FVIII-Fc will result 
from an equilibrium between the respective expression of the activating and inhibitory Fc 
receptors, the affinity of the Fc portion for the different FcRs and for FcRn, and the 
concentration of FVIII-Fc in the circulation at a given time point. Of note, our unpublished 
data show that injection of high doses of C2 domain of FVIII fused to the mouse Fc1 results 
in production of anti-C2 IgG by FVIII-deficient mice. Hence, the manifestation of 
immunogenicity may be highly dependent on the individual molecules that are fused to the Fc 
fragment.  
Interestingly, Fc-mediated interactions also play a role in the context of secondary immune 
responses, once FVIII-specific T and B cells have been activated and have proliferated. 
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Indeed, FcRIIB is the only Fc receptor that is constitutively expressed by B cells. It has been 
demonstrated that cross-linking of the B cell receptor (BcR) and of the low affinity FcRIIB 
inhibits B cell activation and proliferation in an antigen-specific manner, thus ablating 
humoral immune responses [18]. Despite the recent demonstration that FcRIIB is required 
for the differentiation of FVIII-specific memory B cells into antibody-secreting plasma cells 
in mice [19], the data suggest that FVIII-Fc may anergize FVIII-specific B cells and favor 
immune tolerance (Figure 1B). 
Tolerance through regulatory T cell epitopes. The CH2 domain of the IgG Fc fragment 
contains atypical T cell epitopes, which during co-presentation of Fc with associated antigen, 
has been shown to expand antigen-specific CD4
+
CD25
high
Foxp3
+
 regulatory T cells (Tregs) 
[20]. Fc-derived regulatory T cell epitopes, referred to as Tregitopes, were also found to 
confer tolerance to recombinant adeno-associated virus gene transfer vectors [21]. The 
presence of such Tregitopes in the FVIII-Fc molecules may present an advantage in favoring 
the induction of Tregs that would prevent the onset of deleterious anti-FVIII immune 
responses (Figure 1B). However, the efficiency of Tregitope-mediated Treg generation may 
depend on the frequency of administration of Fc-fused proteins, and variations in circulating 
concentrations of FVIII-Fc could drive opposite effects in terms of immune regulation. 
The development of the FVIII-Fc platform nevertheless offers tremendous opportunities for 
generating less immunogenic FVIII products in the future. For instance, the introduction of 
mutations in the Fc portion may favor immune tolerance induction by fine-tuning the affinity 
for particular Fc receptors, provided that expanding the half-life of FVIII-Fc by raising the 
affinity of the Fc fragment for the FcRn does not alter the interactions with the inhibitory 
FcRIIB receptor. In another example, the therapeutic infusion of FVIII-Fc via the 
subcutaneous route may open up new regimens for immune tolerance induction. Dendritic 
cells, and in particular skin dendritic cells, contribute to tolerogenic or immunogenic 
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responses depending on the acquired activation signals [22]. Thus, the commitment of 
epidermal Langerhans cells in inducing antigen-specific tolerance could be exploited with 
FVIII-Fc [23].  
Lastly, FcRn is expressed on the syncytiotrophoblast where it mediates the transfer of 
maternal IgGs to the fetal circulation [1]. In an animal model of mucopolysaccharidosis, Fc-
fused β-glucoronidase injected to pregnant mice was found to be transported through the 
placenta, thus correcting β-glucoronidase deficiency in the offspring [24]. In a recent proof-
of-concept study, the transplacental transfer of Fc-fused A2 and C2 domains of FVIII from 
pregnant mice to the hemophilic fetuses was able to confer long-lasting immune tolerance to 
therapeutic FVIII [25]. Tolerance to FVIII was mediated by FVIII-specific Tregs generated 
during the fetal development of the immune system. The latter work provides novel 
perspectives for the materno-fetal transfer of FVIII-Fc to to-be-born hemophilic babies, at the 
time of immune ontogeny, to confer life-long tolerance to FVIII.  
 
Coupling therapeutic FVIII to human albumin 
Accounting for 50% of total plasma proteins, albumin is the most prominent protein 
circulating in the blood. Serum albumin is a natural carrier for several endogenous 
hydrophobic molecules, such as fatty acids or thyroid hormones; it is also involved in 
scavenging free radical species that may be released in the blood. Albumin displays a long 
half-life of 20 days in vivo. This persistence is attributed to both a high hydrodynamic size, 
which prevents glomerular filtration by kidneys, and interactions with the FcRn receptor 
expressed on endothelial cells, which redirects the internalized albumin to the blood stream. 
Such an extended half-life makes serum albumin an attractive fusion partner to prolong the 
residence time of therapeutic drugs. Conjugation can be performed by a covalent attachment 
of albumin to the drug or by the fusion of the genes encoding human serum albumin and the 
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therapeutic protein of interest [26].Several recombinant albumin-fused proteins have been 
successfully generated and are available on the market or currently tested in clinical trials 
[27]. For instance, albumin-coupled glucagon-like peptide 1 (Albiglutide®, 
GlaxoSmithKline) has been developed to treat type II diabetes. Clinical studies have 
demonstrated that a dramatic prolongation of circulation time after a single infusion of 
Albiglutide®, from 5 minutes for the native glucagon-like peptide 1 (GLP-1) to 5 days for the 
albumin-fused molecule [28]. Recent phase 3 trial confirmed the efficacy of Albiglutide® 
[29], where Albiglutide® infusions successfully ameliorate glycemic control in type II 
diabetic patients. Nonetheless, 3.7% of treated patients were found to develop anti-
Albiglutide® antibodies. The occurrence of anti-Albiglutide® antibodies was however 
transient and did not neutralize GLP-1 efficacy.  
CSL-Behring® (Marburg, Germany) has developed an array of albumin-fused coagulation 
factors for the treatment of hemostatic conditions (patent WO 2011020866 A2, [30]). 
Inhibitor-positive patients with hemophilia A can be treated with activated factor VII (FVIIa). 
However, the short half-life of FVIIa (2.5 hours) requires chronic injections to maintain 
correct hemostasis. A recombinant FVIIa fused to albumin has been generated (rVIIa-FP) 
[31] that presents with a hemostatic activity similar to that of recombinant FVIIa. Clinical 
trials have highlighted the pharmacokinetic parameters of rVIIa-FP, with enhanced circulation 
time and lower clearance rate, and the safety of the product, as none of the rVIIa-FP-treated 
patients developed an anti-rVIIa-FP immune response [32]. Recombinant FIX-albumin, 
referred as rIX-FP, has also been produced and exhibits a 2- to 4-fold prolonged half-life 
compared to the non-fused form when administered to previously treated patients with severe 
hemophilic B [33]. Likewise, none of the participants developed anti-rIX-FP inhibitory 
antibodies. An albumin-fused FVIII has also been generated and patented (termed as rVIII-
FP). However, rVIII-FP failed to maintain FVIII pro-coagulant activity and no further study 
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was published [34]. Some studies have highlighted limitations for albumin conjugation [35], 
such as the risks of incorrect folding of chimeric proteins that is likely to lead to a loss of 
therapeutic activity.  
Since albumin is the most abundant protein in the blood, it is not likely that exogenously 
administered albumin will be recognized as a foreign antigen. This is indirectly suggested by 
the fact that the massive intravenous administration of albumin to patients suffering from 
acute hypovolemia has never been reported to elicit anti-albumin antibodies [36]. Hence, 
albumin-fused coagulation factors are not expected to exhibit immunogenic properties, and 
should elicit immune tolerance or ignorance. Besides, albumin might mask by steric 
hindrance putative antigenic epitopes expressed on therapeutics and impede any deleterious 
recognition by immune cells that may lead to premature clearance or immunogenic uptake by 
antigen presenting cells (APC). Importantly, in silico T cell epitope mapping studies have 
identified six potential Tregitopes within human albumin [37]. One of the Tregitopes is also 
found in bovine serum albumin. Interestingly, infusion of BSA in a murine model of 
atherosclerosis was shown to lower the severity of the pathology [38]. This was correlated 
with the expansion of circulating Tregs in vivo and production of immunosuppressive 
cytokines by splenocytes in vitro. However, a direct role for the Tregitope in the induction of 
tolerance was not demonstrated. 
 
PEGylation of therapeutic FVIII 
PEGylation consists in a covalent conjugation of polymers of ethylene glycol (PEG) to a 
carrier. PEGylation was found to extend the residence time of derivatized proteins [39,40], 
and was therefore considered as an efficient strategy to improve drug delivery and has been 
applied to enhance the lifespan of a large number of drugs over the last decades. PEG 
conjugation affects the physicochemical features of the target protein, without altering its 
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structure. In particular, the hydrophilic property of PEG increases protein solubility in the 
bloodstream and dramatically enhances the hydrodynamic size of the conjugate, thus 
tempering glomerular filtration rate and significantly prolonging the circulation time in the 
body [41]. Moreover, PEG prevents the aggregation of derivatized proteins and hampers 
interactions with catabolic receptors, which also impedes a premature clearance from the 
circulation.  
Based on these findings, PEGylation has been extensively exploited to generate long-lasting 
recombinant coagulation FVIII, such as BAY 94-9027, BAX 855 and N8-GP. PEGylation of 
FVIII was shown to confer prolonged efficacy in hemophilic mice, as compared to 
unmodified FVIII. BAY 94-9027, a single branched 60 kDa PEG-coupled B domain-deleted 
FVIII developed by Bayer, not only retains a full activity after PEGylation, but also exhibited 
enhanced pharmacokinetic parameters, with a 2 to 3-fold increase of circulating half-life as 
compared to non-PEGylated FVIII [42]. Recent phase I clinical trial has confirmed the longer 
half-life in humans, although the extension was less significant than in animal models, with a 
1.5-fold increase (18.5 hours versus 13 hours for its non-PEGylated version) [43]. 
Furthermore, infusion of BAY 94-9027 to patients was not reported to elicit inhibiting 
antibodies. Likewise, PEGylation of Baxter’s recombinant full-length FVIII Advate™ (BAX 
855, 20 kDa PEG) has generated an improved molecule that exhibits a 1.8-fold extension of 
circulating time in primates compared to native FVIII and that delays by 3 folds the time to 
reach trough level [44]. PEGylation of FVIII impedes the binding of BAX 855 to the low 
density lipoprotein receptor protein 1 (LRP-1), a catabolic receptor for FVIII, which accounts, 
at least in part, for the longer persistence of the molecule in the bloodstream. A recent clinical 
trial has highlighted a modest 1.5-fold increase of BAX 855 half-life [45]. Prophylactic 
regimen performed over several months on PTPs was not associated with the generation of 
neutralizing antibodies. Similarly, Novo-Nordisk has developed a glycoPEGylated version of 
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a B-domain deleted FVIII (N8-GP, 40 kDa PEG coupled to B domain) which displays a 2-
fold prolonged half-life in animal models of hemophilia A, as well as an extended hemostatic 
potential compared to uncoupled FVIII [46,47]. N8-GP was also shown to interact less with 
the catabolic receptor LRP-1. Clinical trials in PTPs with severe hemophilia A did not report 
the generation of anti-FVIII neutralizing antibodies [48].  
From an immunological point of view, PEG theoretically gathers several characteristics that 
make it an ideal partner. PEGylation has been shown to annihilate the immunogenicity of 
heterologous proteins after administration to animals, as compared to the non-PEGylated 
counterparts [49]. The PEG moiety can mask structures that are recognized by endocytic 
receptors expressed on APC and hampers the uptake of the drug (Figure 1C). Besides, even if 
PEGylated biopharmaceutics are internalized, the processing that leads to the presentation of 
derived peptides onto major histocompatibility complex (MHC) class II molecules may be 
hampered by PEG-mediated steric hindrance. Alternatively, PEGylated peptides can be 
presented on APC surface, but may however not be recognized by T helper cells, thus 
preventing T cell activation, limiting the activation of antigen-specific B cells and, as a result, 
reducing the risk for the generation of anti-drug antibodies. In the case of FVIII, 
administration of BAY 94-9027 to hemophilic mice was correlated with a lower incidence of 
anti-FVIII antibodies and a reduction in the FVIII-specific T cell immune response. Besides, 
PEGylation, upon masking essential glycoprotein moieties involved in FVIII recognition, was 
shown to interfere with its uptake and presentation by human dendritic cells [50], and thus 
hindered the ensuing immunogenic presentation of FVIII-derived peptides to specific CD4
+
 T 
cells. Similarly, in vitro assays show that N8-GP binds less to human dendritic cells and is 
less internalized by these cells [46]. While any structural alteration of the FVIII molecule 
introduces a risk to enhance its immunogenicity, the generation of immunogenic B or T cell 
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neo-epitopes within PEGylated FVIII is not supported by the available clinical studies, and no 
clear increase in the incidence of FVIII inhibitor has been reported up to date. 
Safety and immunological aspect of PEG. Since PEG is a chemical compound that cannot 
be readily metabolized by the organism, concerns have been raised regarding its 
elimination/accumulation in the organism. It has been documented that PEG is cleared from 
the circulation through urinary excretion [51]. However, several studies have emphasized 
histological alterations in various organs and tissues, consecutive to the administration of 
PEG or PEGylated proteins. Infusion of PEGylated proteins was associated with a massive 
cytoplasmic vacuolation, evidenced in the kidney tubular epithelium [52] as well as in the 
reticuloendothelial system. These changes supposedly resulted from a deformation of 
lysosomes after the uptake of PEGylated proteins during their clearance process or by 
pinocytosis. Besides, the occurrence of foamy macrophages has been described after an 
iterative administration of PEG or PEGylated biotherapeutics [52–54]. PEG injection in rats 
led to a cellular vacuolation that occurred in different locations, such as lung alveolar 
macrophages, hepatic Kupffer cells or splenic subcapsular red pulp histiocytes, where PEG 
was found to accumulate [53]. Since the reticuloendothelial system is a component involved 
in the clearance of cellular debris and foreign bodies, accumulation of PEG and vacuolation at 
the level of macrophages are part of a physiological mechanism. Nevertheless, issues have 
been raised about a putative toxicity of PEG, especially in a context (i.e., hemophilia) where 
administration of the PEGylated drug is chronic and starts during infancy. Of note, 
administration of high doses of PEGylated proteins to rodents was associated with splenic 
hypertrophy and an extensive vacuolation of splenic histocytes [55]. Likewise, Young et al. 
demonstrated that infusion of maleimide-PEG-modified hemoglobin in primates is associated 
with the occurrence of foamy macrophages in the spleen and in the bone marrow [56]. 
Intriguingly, macrophage functions and phenotype were either not evaluated or not altered by 
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vacuolation in vivo. However, mouse and human macrophages incubated with certolizumab 
pegol (PEGylated anti-tumor necrosis factor alpha, Cimzia®) in vitro showed a lower 
phagocytic ability for bacteria and fungi (report EMEA/664021/2009). Yet, no evidence 
regarding altered immune responses was found in vivo and the safety of Cimzia® was 
supported by preclinical and clinical studies, as no major adverse events was reported. 
Importantly, although vacuolation in tissues or in macrophages has been reported for several 
biopharmaceuticals commercially available or in clinical trials [51], the administration of 
BAX 855 to animals did not generate overt vacuolation [57].  
While PEG is assumed to be neither antigenic nor immunogenic, an increasing number of 
studies provides evidence that administration of PEGylated products triggers unexpected anti-
PEG antibody production [58]. Thirty years ago, Richter and Akerblom demonstrated the 
generation of anti-PEG IgM antibodies in rodents after injections of PEGylated ovalbumin, 
while PEG injected alone did not elicit an antibody response [59,60]. In humans, anti-PEG 
antibodies have been reported in hepatitis C patients treated with PEGylated interferon, but 
the presence of anti-PEG antibodies was not associated with an impairment of the efficacy of 
interferon [61]. Conversely, in acute lymphoblastic leukemia, one third of the patients treated 
with PEGylated asparaginase presented with anti-PEG IgM antibodies, which were closely 
associated with a loss of function and an accelerated clearance of the molecule [62]. Whereas 
the exact mechanism for anti-PEG antibody elicitation remains unknown, several 
investigations have been performed to decipher the immunogenicity of PEG. Chronic 
intravenous infusion in mice of PEGylated liposomes, which are often used as a carrier for 
biopharmaceuticals, was correlated to an accelerated blood clearance and a marked reduction 
in bioavailability [63–65]. The anti-PEG immune response involves B cells from the marginal 
zone of the spleen and is characterized by a lack of immunoglobulin class switching as well as 
the absence of generation of memory B cells [66–70]. Therefore, the immune response 
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develops in a thymo-independent manner. As PEG is constituted of multiple repeated 
patterns, it may be regarded as a type II antigen, similar to bacterial polysaccharides, and it 
may simultaneously engage several BcR expressed on the surface of B cells. This massive 
cross-linking of BcR is sufficient to induce the full differentiation of naïve B cells into IgM-
secreting plasmocytes. Lastly, some reports suggest that PEGylated biotherapeutics are able 
to activate the complement system [71,72]. Complement activation leads to opsonization of 
the biotherapeutics by C3-derived fragments that may promote interactions with macrophages 
through complement receptors. This may participate in the accelerated decay of PEGylated 
pharmaceuticals, but may also induce pro-inflammatory anaphylatoxins, that can activate 
granulocytes and trigger hypersensitivity responses. Such a phenomenon probably accounts 
for the few cases of anaphylaxis observed in clinical trials, for instance in the case of 
treatment with PEGylated liposomal doxorubicin [73].  
Of note, immunogenicity studies in mice have shown that some forms of PEGylated FVIII 
evoke an anti-FVIII immune response, and are able to break immune tolerance the FVIII 
moiety [74]. However the incriminated molecule exhibited 12 molecules of PEG per molecule 
of FVIII and drastically reduced specific activity, thus highlighting probable major structural 
modifications.  
 
Conclusions 
The development of a new generation of therapeutic coagulation factors is revolutionizing the 
treatment of patients with hemophilia. Specifically, novel products with extended half-lives 
should facilitate patient management, resulting in a drastically improved quality of life. 
Indeed, the reduced frequency of drug administration and the prolonged circulation time of 
the hemostatic drugs should provide a longer protection of the patients from micro-bleeds in 
joints, thus minimizing co-morbidity. In the particular case of pro-coagulant FVIII, among the 
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three strategies developed to date, only Fc-fusion and PEGylation have yielded encouraging 
results and been translated to the patients, while albumin-fusion FVIII has failed. Yet, several 
issues remain to be addressed to develop products with unquestioned efficacy and safety.  
One such question addresses the somewhat limited gain in half-lives of the Fc-fused and 
PEGylated FVIII products that do not exceed the circulation time of FVIII imposed by 
binding to its chaperone VWF. It is probable that VWF is endowed with a double-edged role 
towards FVIII catabolism, on one hand reducing the binding of FVIII to major catabolic 
receptors, but also on the other hand participating in, and probably leading, FVIII endocytosis 
by macrophages both in vivo and in vitro [75,76]. Under such conditions, it is probable that 
drastic gains in FVIII half-life for the new generation therapeutics will be achieved in setups 
that eliminate the part of FVIII catabolism mediated by VWF moieties, as may be the case in 
a recently developed recombinant FVIII-Fc/D’D3-Fc construct (patent WO 2013106787 A1).  
One other important issue is that of the ever-astonishing intrinsic immunogenicity of the very 
FVIII molecule. While most biotherapeutics induce anti-drug antibodies in <5% of the 
patients, FVIII triggers inhibitory immune responses in up to 30% of patients with hemophilia 
A. FVIII remains an enigma in terms of immunogenicity, in view of the facts that it is injected 
intravenously, a known tolerogenic route of administration and in low amounts. A role for its 
pro-coagulant function in generating a burst of thrombin [77,78], the presence of incomplete 
glycans on its heavy and light chain that may favor immunogenic uptake by antigen-
presenting cells [79,80] as well as the presence of particularly immune-dominant T cell 
epitopes have been proposed to explain anti-FVIII immune responses [81–83]. FVIII 
immunogenicity is further highlighted by its capacity to confer immunogenicity to otherwise 
immunologically inert molecules. This has been demonstrated by the work of van Helden et al 
in the case of PEG [74], and may also be observed in the case of fused protein moieties as 
seen in our unpublished experiments wherein fusion of the FVIII light chain to hemagglutinin 
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drastically increased the anti-hemagglutinin immune response in FVIII-deficient mice (Figure 
2).  
Another critical issue is the mechanistic investigation of the immunogenicity of newly 
generated coagulation factors and the requirement of experimental models that mimic 
immune responses observed in humans and that are devoid of biasing inter-species immune 
reactions. In particular, studying the immunogenicity of Fc-fused FVIII in FVIII-deficient 
mice may be biased by putative immune responses directed to the human Fc fragment, which 
would presumably not occur in the patients. Ideally, the immunogenicity of human FVIII 
should be evaluation using appropriate humanized animal models able to mount IgG-
mediated humoral immune responses, in order to obtain relevant and basic immunological 
insights translatable to the bedside. Resolving the aforementioned concerns, the in-depth 
immunological investigations of new generation long-lasting coagulation factors should be of 
priority in the hemophilia research domain. 
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Figures 
Figure 1. Potential effects of FVIII alterations on the onset of the immune response 
against FVIII. Panel A. The anti-FVIII immune response is considered as a classical T-
dependent immune response where exogenous FVIII is endocytosed by antigen presenting 
cells (APC), processed and presented to naïve FVIII-specific T lymphocytes that get 
activated. The latter will activate B lymphocytes, which will differentiate into inhibitory 
antibody-secreting plasma cells. Panel B. Fusion of Fc fragment to FVIII may facilitate the 
cross-linking of surface B cell receptors (BcR) and inhibitory FcγRIIb receptors, thus 
anergizing B cells (left). Fc fragment may interact with FcγRIIb receptors expressed on APC 
and impede their maturation, leading to FVIII-derived peptides antigenic presentation in a 
tolerogenic context (middle). Fc moiety might bring about regulatory T cell epitopes 
(Tregitopes) that would boost Fc-specific regulatory T cells (Tregs). Tregs would then induce 
a bystander tolerance to FVIII (right). Panel C. PEGylation of FVIII may prevent the uptake 
of FVIII by APC. Even if it is endocytosed, PEG moiety may alter FVIII processing and 
presentation to T lymphocytes. Finally, PEGylation may also mask B cells epitopes and 
prevent FVIII recognition by neutralizing antibodies. 
Figure 2. Adjuvant effect of the light chain of human FVIII. The recombinant first domain 
of hemagglutinin (HA1), and the recombinant fused A3C1C2-HA1 (LCh-HA1) were 
produced using the HKB11 eukaryotic cell line. The light chain of FVIII (a3A3C1C2, LCh) 
was purified from therapeutic FVIII. FVIII-deficient mice were injected with the different 
proteins (1 pmol of each protein/mouse) once a week for four weeks. Five days after the 
fourth injection, anti-HA1 IgG were detected by ELISA. Levels of anti-HA1 IgG are depicted 
in arbitrary unit based on the optical density measured at 492 nm, and were statistically 
compared using the two-sided non-parametric Mann-Whitney test. Individual symbols 
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represent levels of specific IgG for each individual mouse, and horizontal bars represent 
mean±SEM.  
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